New antiepileptic drugs, cost-efficacy analysis
Objective: to optimize pharmacotherapy in patients with epilepsy and to evaluate the clinical and cost-effectiveness of its therapy with the new antiepileptic drugs (AED): levetiracetam, lamotrigine, topiramate, and oxcarbazepine.Patients and methods. The study enrolled 134 patients (women, 69.03%;...
Main Authors: | P. N. Vlasov, N. V. Orekhova, T. I. Konovalova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2014-01-01
|
Series: | Неврология, нейропсихиатрия, психосоматика |
Subjects: | |
Online Access: | https://nnp.ima-press.net/nnp/article/view/226 |
Similar Items
-
Association of Vitamin D Deficiency with Antiepileptic Drugs in Patients with Epilepsy
by: Oya ÖZTÜRK, et al.
Published: (2020-08-01) -
Generalized epilepsies: current conceptions and therapeutic approaches
by: L R Zenkov
Published: (2012-03-01) -
Cognitive effects of lamotrigine versus topiramate as adjunctive therapy in older adults with epilepsy
by: Steve S. Chung, et al.
Published: (2009-07-01) -
Levetiracetam versus Oxcarbazepine as monotherapy in newly diagnosed focal epilepsy: A systematic review and meta‐analysis
by: Sanjeev Kharel, et al.
Published: (2022-11-01) -
Efficacy and safety of levetiracetam vs. oxcarbazepine in the treatment of children with epilepsy: a systematic review and meta-analysis
by: Yuanyuan Liu, et al.
Published: (2024-04-01)